We are live on
!
Find out more
Handelsbanken Fonder Portfolio holdings
AUM
$35.1B
1-Year Est. Return
47.76%
This Fund
S&P 500
This Quarter
Est. Return
+5.05%
1 Year Est. Return
+47.76%
3 Year Est. Return
+137.96%
5 Year Est. Return
+170.36%
10 Year Est. Return
+934.7%
AUM
$5.4B
AUM Growth
+$238M
(+4.6%)
Cap. Flow
+$43.6M
Cap. Flow
% of AUM
0.81%
Top 10 Holdings %
Top 10 Hldgs %
27.43%
Holding
200
New
18
Increased
64
Reduced
88
Closed
11
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
AbbVie
ABBV
|
+$29.9M |
| 2 |
WIFI
Boingo Wireless, Inc.
WIFI
|
+$29.4M |
| 3 |
Columbia Sportswear
COLM
|
+$27.3M |
| 4 |
Eli Lilly
LLY
|
+$23.2M |
| 5 |
Alibaba
BABA
|
+$22.5M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Johnson & Johnson
JNJ
|
+$29.7M |
| 2 |
Apple
AAPL
|
+$28.4M |
| 3 |
NetEase
NTES
|
+$21.5M |
| 4 |
MLNX
Mellanox Technologies, Ltd.
MLNX
|
+$20.2M |
| 5 |
Las Vegas Sands
LVS
|
+$19.1M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Consumer Discretionary | 19.96% |
| 2 | Healthcare | 19.22% |
| 3 | Technology | 14.17% |
| 4 | Financials | 13.61% |
| 5 | Industrials | 13.08% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
151
Martin Marietta Materials
MLM
$32.7B
| $6.79M | 0.13% |
29,500
| – | – |
|
152
Gilead Sciences
GILD
$168B
| $6.7M | 0.12% |
99,157
-69,495
| -41% | -$4.57M |
|
|
BHVN
153
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
| $6.66M | 0.12% |
+152,000
| New | +$8.57M |
|
|
ABMD
154
DELISTED
Abiomed Inc
ABMD
| $6.64M | 0.12% |
25,500
-6,000
| -19% | -$1.59M |
|
155
Evolent Health
EVH
$471M
| $6.36M | 0.12% |
800,000
+325,000
| +68% | +$3.85M |
|
|
TRHC
156
DELISTED
Tabula Rasa HealthCare, Inc. Common Stock
TRHC
| $6.24M | 0.12% |
+125,000
| New | +$6.22M |
|
157
Cognex
CGNX
$10.2B
| $6.24M | 0.12% |
130,000
-50,000
| -28% | -$2.4M |
|
158
ReposiTrak
TRAK
$152M
| $6.18M | 0.11% |
1,153,641
+1,092,683
| +1,793% | +$7.26M |
|
159
Gates Industrial Corporation Ltd.
GTES
$7.05B
| $5.71M | 0.11% |
500,000
+170,000
| +52% | +$2.28M |
|
160
TAL Education Group
TAL
$6.58B
| $5.28M | 0.1% |
138,500
+20,000
| +17% | +$723K |
|
161
Universal Display
OLED
$4.23B
| $4.95M | 0.09% |
26,312
-18,832
| -42% | -$3.13M |
|
162
National Vision
EYE
$1.56B
| $4.39M | 0.08% |
143,000
-55,000
| -28% | -$1.58M |
|
|
MRTX
163
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $4.22M | 0.08% |
41,000
+1,000
| +3% | +$77.9K |
|
164
Digimarc Corp
DMRC
$167M
| $4M | 0.07% |
90,000
+20,000
| +29% | +$912K |
|
165
Everspin Technologies
MRAM
$415M
| $3.91M | 0.07% |
600,000
| – | – |
|
166
Sarepta Therapeutics
SRPT
$1.94B
| $3.27M | 0.06% |
21,500
-5,000
| -19% | -$608K |
|
167
CryoPort
CYRX
$750M
| $2.93M | 0.05% |
+160,080
| New | +$2.54M |
|
|
JKS
168
JinkoSolar
JKS
$860M
| $2.89M | 0.05% |
133,273
-200,455
| -60% | -$4.05M |
|
|
REED
169
DELISTED
Reeds, Inc. Common Stock
REED
| $2.27M | 0.04% |
12,000
+11,400
| +1,900% | +$2.01M |
|
|
MYOK
170
DELISTED
MyoKardia, Inc. Common Stock
MYOK
| $2.16M | 0.04% |
43,000
-10,000
| -19% | -$487K |
|
171
Nektar Therapeutics
NKTR
$2.57B
| $2.1M | 0.04% |
3,936
-1,080
| -22% | -$542K |
|
|
COHR
172
DELISTED
Coherent Inc
COHR
| $1.99M | 0.04% |
14,604
-1,710
| -10% | -$231K |
|
173
Trip.com Group
TCOM
$28.7B
| $1.85M | 0.03% |
+50,000
| New | +$1.97M |
|
174
Loop Industries
LOOP
$32.2M
| $1.45M | 0.03% |
146,625
+126,625
| +633% | +$987K |
|
175
Minerva Neurosciences
NERV
$187M
| $1.44M | 0.03% |
31,875
| – | – |
|
Similar funds
VIA
Handelsbanken Fonder's Q2 2019 Portfolio in Review
As of Q2 2019, Handelsbanken Fonder held 200 positions worth $5.4B, up 4.6% from $5.17B the previous quarter. Its ten largest holdings account for 27% of the portfolio.
Handelsbanken Fonder's Q2 2019 filing shows 18 new, 64 increased, 88 reduced and 11 closed positions. Its largest new stake was JD.com: 650,000 shares worth $19.7M. The largest sale was Johnson & Johnson, an estimated $29.7M.
By sector, the portfolio is most concentrated in Consumer Discretionary at 20% of assets, up from 19% a quarter earlier, followed by Healthcare and Technology.
- Handelsbanken Fonder's largest Q2 2019 buy was JD.com: 650,000 shares worth $19.7M.
- Handelsbanken Fonder added most to AbbVie in Q2 2019, an estimated $29.9M increase.
- Handelsbanken Fonder's biggest Q2 2019 reduction was Johnson & Johnson, cutting an estimated $29.7M.
- Handelsbanken Fonder fully exited Las Vegas Sands in Q2 2019, selling an estimated $19.1M.
- Handelsbanken Fonder's ten largest holdings make up 27% of its $5.4B portfolio in Q2 2019.
- Handelsbanken Fonder opened 18 new positions and closed 11 in Q2 2019.
- Handelsbanken Fonder's portfolio value rose 4.6% quarter-over-quarter to $5.4B.
Based on Handelsbanken Fonder's 13F filing for Q2 2019, filed 12 Jul 2019.